Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl)
Journal of Thrombosis and Haemostasis · 2024
DOI: 10.1016/j.jtha.2024.08.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Panpan Meng und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, Chi…. Hauptthemen laut MEDLINE: Receptors, Thrombopoietin, Zebrafish, Thrombopoiesis, Paclitaxel. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Gefördert von: Key Technologies Research and Development Program, Guangdong Provincial Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Platelets are critical for thrombosis and hemostasis. The THPO-MPL pathway is the primary pathway for generating thrombocytes. Dysregulation of thrombopoiesis results in platelet formation and/or function-related disorders, such as thrombocytopenia. Paclitaxel is an extensively utilized chemotherapeutic agent and its activity may be related to platelets, but the effect of paclitaxel on thrombocytopoiesis warrants comprehensive exploration. OBJECTIVES: We focused on identifying factors that regulate thrombocyte production and elucidating paclitaxel's regulatory mechanisms on thrombocytopoiesis, with a particular emphasis on discovering mechanisms that bypass THPO-MPL pathways. METHODS: We performed drug screenings using the Tg(mpl:eGFP) zebrafish model in vivo to identify Food and Drug Administration-approved compounds capable of boosting thrombocyte production. An injury experiment was used to evaluate thrombocyte function. Bromodeoxyuridine assays, terminal deoxynucleotidyl transferase dUTP nick-end labeling, and RNA sequencing analyses were performed to explore cytological and molecular mechanisms. Routine blood testing and flow cytometry were used to analyze mouse phenotypes. RESULTS: We found that paclitaxel expands thrombocytes by accelerating the proliferation of thrombocytic lineage cells in zebrafish and elevates platelet levels in mice. This effect occurs by bypassing the thrombopoietin receptor (Mpl). We found that paclitaxel promotes thrombopoiesis, potentially involving the JAK2-ERK1/2 MAPK signaling cascade, a pathway integral to MPL and other regulators. Our results further demonstrate that ERK1/2 is at least partially downstream of JAK2 in paclitaxel-induced thrombopoiesis. CONCLUSION: Paclitaxel could promote thrombopoiesis by bypassing Mpl but presumably via the JAK2-ERK1/2 MAPK pathways. It will aid in understanding the relationship between paclitaxel and platelets clinically, and paclitaxel may have potential value for safeguarding platelets and improving thrombocytosis in related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, China; Key Laboratory of Zebrafish Modeling and Drug Screening for Human…
- The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, China.
- Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Guangdong Higher Education Institutes, Department of Developmental Biology, School of Basic Medical Sciences, Southern Medical University, Gu…
- State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Army Medical University, Chongqing, China.
- Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.
- The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, China; Department of Hematology, the Sixth Affiliated Hospital, School of…
Förderung
- Key Technologies Research and Development Program
- Guangdong Provincial Natural Science Foundation
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Guangdong Province Higher Vocational Colleges and Schools Pearl River Scholar Funded Scheme
Zitieren
APA
Meng, P., Liu, W., Lao, J., Liu, X., Zhang, Y., Sun, Y., Zhou, R., Du, C., Wang, J., Zhao, D., Lin, Q., & Zhang, Y. (2024). Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl). Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.08.025
Vancouver
Meng P, Liu W, Lao J, Liu X, Zhang Y, Sun Y, et al. Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl). Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.08.025
BibTeX
@article{Meng2024,
author = {Meng, Panpan and Liu, Wenyu and Lao, Jiawen and Liu, Xunwei and Zhang, Yangping and Sun, Ying and Zhou, Riyang and Du, Changhong and Wang, Junping and Zhao, Dejian and Lin, Qing and Zhang, Yiyue},
title = {Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl)},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
doi = {10.1016/j.jtha.2024.08.025}
}
EUVIMED